If you are a Healthcare Professional and you would like to log in to access this content, please click "Login".
You are now leaving the Lilly Medical Web site
Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Taltz Summary of Product Characteristics (SmPC)
Taltz® ▼ (ixekizumab): Method of Administration in Adults
Ixekizumab is for subcutaneous injection.
is intended for use under the guidance and supervision of a physician
experienced in the diagnosis and treatment of conditions for which
Ixekizumab is indicated.1
is for subcutaneous injection. Injection sites may be alternated. If
possible, areas of the skin that show psoriasis should be avoided as
injection sites. The solution/the syringe must not be shaken.1
ixekizumab injection is to be administered
a different anatomic location (such as upper arms, thighs, or any
quadrant of the abdomen) than the previous injection, and
into areas where the skin is tender, bruised, erythematous,
indurated, or affected by psoriasis.2
into the upper outer arm may be performed by a caregiver or
proper training in subcutaneous injection technique, patients may
self-inject ixekizumab if a healthcare professional determines that
it is appropriate. However, the physician should ensure appropriate
follow-up of patients. Comprehensive instructions for administration
are given in the package leaflet and the user manual.1
are 2 presentations for ixekizumab.
80 mg/ml solution is contained in a single-dose prefilled pen.
80 mg/ml solution is contained in a single-dose prefilled syringe.1
Taltz [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.
Date of Last Review:June 17, 2020
Was this answer helpful to you?
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at firstname.lastname@example.org